Oct 23 (Reuters) – Bristol-Myers Squibb Company: * BRISTOL MYERS SQUIBB PRESENTS RESULTS FROM PHASE 1 BREAKFREE-2 STUDY OF ZOLACABTAGENE AUTOLEUCEL (BMS-986353) IN PATIENTS WITH HIGHLY ACTIVE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Los Angeles Rams wide receiver Puka Nacua is questionable for Sunday's game at Las Vegas…
VIDEO SHOWS: ARCHIVE OF BAYERN MUNICH COACH VINCENT KOMPANY / SCREENGRAB FROM STATEMENT FOR CLUB…
By Nicole Jao NEW YORK, Oct 23 (Reuters) - Oil prices rose on Friday, with…
(Updates prices; adds comments, market activity throughout) * Brent, WTI head for weekly gains *…
By Caroline Humer NASHVILLE, Oct 23 (Reuters) - Billionaire entrepreneur Mark Cuban said on Friday…
Here are the top sports stories and upcoming coverage plans for Reuters text service as…